Inventor

CAMPHAUSEN RAY

US48 patents

⚠️ This page may combine multiple inventors who share the name “CAMPHAUSEN RAY”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

CAMPHAUSEN RAY

BRISTOL MYERS SQUIBB CO

Modified FGF-21 polypeptides comprising an internal deletion and uses thereof

Bispecific EGFR/IGFIR binding molecules

Bispecific EGFR/IGFIR binding molecules

Targeted therapeutics based on engineered proteins that bind EGFR

Multivalent fibronectin based scaffold domain proteins

Method of treating cancer by administering EGFR and EGFR/IGFIR binding molecules

Targeted therapeutics based on engineered proteins that bind EGFR

Therapeutic uses of modified FGF-21 polypeptides

Fibronectin binding domains with reduced immunogenicity

Modified FGF-21 polypeptides comprising an internal deletion and uses thereof

Serum albumin binding molecules

Fibronectin binding domains with reduced immunogenicity

Fibronectin binding domains with reduced immunogenicity

Serum albumin binding molecules

Fibronectin based scaffold domain proteins that bind PCSK9

Fibronectin based scaffold domain proteins that bind PCSK9

Fibronectin binding domains with reduced immunogenicity

Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides

Serum albumin binding molecules

Method of treating cancer by administering multivalent fibronectin based scaffold domain proteins

Serum albumin-binding fibronectin type III domains

Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereof

Polynucleotides encoding bispecific EGFR/IGF-IR binding molecules

Fibronectin based scaffold domain proteins that bind PCSK9

Methods of treating cancer by administering IGF-IR binding molecules

Fibronectin based scaffold proteins having improved stability

Fibronectin binding domains with reduced immunogenicity

Fibronectin binding domains with reduced immunogenicity

Serum albumin-binding fibronectin type III domains

Bispecific EGFR/IGFIR binding molecules

Targeted therapeutics based on engineered proteins that bind EGFR

Fc fusion proteins comprising novel linkers or arrangements

Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR

Fibronectin based scaffold proteins having improved stability

Serum albumin-binding fibronectin type III domains

Nucleic acids encoding modified FGF-21 polypeptides, vectors and cells containing, and use thereof

Fibronectin binding domains with reduced immunogenicity

Fibronectin based scaffold domain proteins that bind PCSK9

CAMPHAUSEN RAY

Fibronectin based scaffold domain proteins that bind to PCSK9

Multivalent fibronectin based scaffold domain proteins

Targeted therapeutics based on engineered proteins that bind EGFR

Multivalent fibronectin based scaffold domain proteins

Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR

Fc fusion proteins comprising novel linkers or arrangements

Fibronectin based scaffold proteins having improved stability

GENETICS INST

P-selectin ligand protein

Method of inhibiting P-selectin ligand activity

GOSSELIN MICHAEL L

Serum albumin binding molecules